Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing ROIV more generously than it does today.
Analysis OverviewBuyUpdated Jun 18, 2026
Roivant Sciences Ltd. (ROIV) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
15
analysts
14 bullish · 0 bearish · 15 covering ROIV
Strong Buy
0
Buy
14
Hold
1
Sell
0
Strong Sell
0
Consensus Target
$37
+18.3% vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
15
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $22.6B
ROIV price targets
Three scenarios for where ROIV stock could go
Current
~$31
Confidence
50 / 100
Updated
Jun 18, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Roivant Sciences Ltd.
ROIV · NASDAQHealthcareBiotechnologyMarch year-end
Roivant Sciences is a biopharmaceutical company that develops and commercializes innovative medicines across multiple therapeutic areas through its network of subsidiary "Vants." It generates revenue primarily from product sales of approved drugs — like its dermatology and immunology treatments — supplemented by licensing deals and research collaborations with larger pharmaceutical partners. Its key advantage is its decentralized "Vant" model, which allows for focused development of individual drug candidates while sharing centralized resources and expertise across the portfolio.
Market Cap
$22.6B
Revenue TTM
$8M
Net Income TTM
-$300M
Net Margin
-3629.2%
ROIV Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
25%Exceptional
vs consensus estimates
Avg EPS Surprise
+12.9%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$-0.18/$-0.25
Revenue
$2M/$7M
Q4 2025
EPS
$-0.20/$-0.32
Revenue
$2M/$6M
Q1 2026
EPS
$-0.24/$-0.30
Revenue
$2M/$5M
Q2 2026
EPS
$-0.28/$-0.29
Revenue
$3M/$3M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $-0.18/$-0.25 | +27.9% | $2M/$7M | -70.3% |
| Q4 2025 | $-0.20/$-0.32 | +36.9% | $2M/$6M | -72.0% |
| Q1 2026 | $-0.24/$-0.30 | +19.9% | $2M/$5M | -60.6% |
| Q2 2026 | $-0.28/$-0.29 | +3.5% | $3M/$3M | -26.2% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$8M
0.0% YoY
FY2
$8M
+2.4% YoY
EPS Outlook
FY1
$-0.00
+99.2% YoY
FY2
$-0.00
— YoY
Trailing FCF (TTM)-$759M
FCF Margin: -9183.5%
Next Earnings
July 1, 2026
Expected EPS
$-0.29
Expected Revenue
$4M
ROIV beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
ROIV Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $8M
Product Mix
Latest annual revenue by segment or product family
Reportable Segment
100.0%
YoY unavailable
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Segment breakdown not available for this company.
Reportable Segment is the largest disclosed segment at 100.0% of FY 2025 revenue, with no year-over-year comparison yet.
ROIV Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Relative Valuation
Benchmark comparison across market, sector, and history below.
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
ROIV
-73.1x
vs
S&P 500
24.4x
399% discount
vs Healthcare Trailing P/E
ROIV
-73.1x
vs
Healthcare
22.1x
430% discount
vs ROIV 5Y Avg P/E
Today
-73.1x
vs
5Y Average
2.0x
3727% discount
Forward PE
—
S&P 500
18.8x
—
Healthcare
18.3x
—
5Y Avg
—
—
Trailing PE
-73.1x
S&P 500
24.4x
-399%
Healthcare
22.1x
-430%
5Y Avg
2.0x
-3727%
PEG Ratio
—
S&P 500
1.66x
—
Healthcare
1.59x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.2x
—
Healthcare
14.2x
—
5Y Avg
—
—
Price/FCF
—
S&P 500
20.7x
—
Healthcare
18.5x
—
5Y Avg
—
—
Price/Sales
2736.9x
S&P 500
3.1x
+88421%
Healthcare
2.6x
+103737%
5Y Avg
—
—
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
0.07%
—
| Metric | ROIV | S&P 500 | Healthcare | 5Y Avg ROIV |
|---|---|---|---|---|
| Forward PE | — | 18.8x | 18.3x | — |
| Trailing PE | -73.1x | 24.4x-399% | 22.1x-430% | 2.0x-3727% |
| PEG Ratio | — | 1.66x | 1.59x | — |
| EV/EBITDA | — | 15.2x | 14.2x | — |
| Price/FCF | — | 20.7x | 18.5x | — |
| Price/Sales | 2736.9x | 3.1x+88421% | 2.6x+103737% | — |
| Dividend Yield | — | 1.91% | 1.50% | 0.07% |
ROIV trades above S&P 500 benchmarks on 1 of 2 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolROIV Financial Health
Verdict
Stressed
ROIV returns 1.4% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$8M
Revenue Growth
TTM vs prior year
-67.7%
Gross Margin
Gross profit as a share of revenue
84.4%
Operating Margin
Operating income divided by revenue
-15560.6%
Net Margin
Net income divided by revenue
-3629.2%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$-0.37
Free Cash Flow (TTM)
Cash generation after capex
-$759M
FCF Margin
FCF as share of revenue — the primary cash quality signal
-9183.5%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
-29.4%
ROA
Return on assets, trailing twelve months
-5.7%
Cash & Equivalents
Liquid assets on the balance sheet
$1.4B
Net Cash
Cash exceeds total debt — no net leverage
$1.3B
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE *
Return on equity, trailing twelve months
-6.0%
* Elevated by buyback-compressed equity — compare ROIC (-29.4%) for an undistorted picture of capital efficiency.
Shareholder Returns
How capital is returned to owners
Total shareholder yield
1.4%
Dividend
—
Buyback
1.4%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$318M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
719M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt). ROE marked * where buyback-compressed equity base may inflate the figure.
Open full ratios pageROIV Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
Medium
Pipeline Execution Risk
Despite a strong balance sheet, Roivant's ability to advance its diversified pipeline and acquire new assets successfully remains uncertain.
High Risk
Revenue Concentration
Full-year 2026 sales of US$8.26 million indicate limited revenue diversification, posing a risk if key products underperform.
Medium
Net Income Volatility
The swing to quarterly net income of US$302.99 million may not be sustainable, given the company's early-stage pipeline.
Lower
Market Sentiment Risk
While the stock has a Buy rating and upside potential, bearish scenarios could emerge from broader biotech sector volatility.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why ROIV Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Brepocitinib Program Expansion
Roivant Sciences is expanding its brepocitinib development program with a new Phase 2b/3 trial in Lichen Planopilaris (LPP), indicating potential growth in its pipeline.
FDA Priority Review for Brepocitinib
The U.S. FDA has accepted Roivant's New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, targeting a potential launch by Q3 2026.
Phase 3 Batoclimab Data Update
Positive Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) could drive investor confidence and future revenue streams.
Positive Stock Momentum
Roivant Sciences' stock is showing modest positive momentum, with intraday gains attracting market attention and signaling investor optimism.
First Targeted Therapy Potential
If approved, brepocitinib would become the first targeted therapy for dermatomyositis, positioning Roivant as a leader in this treatment area.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
ROIV Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$31.43
52W Range Position
94%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$10.71
+193.5% from the low
52-Week High
$32.79
-4.2% from the high
1 Month
+10.09%
3 Month
+13.06%
YTD
+43.3%
1 Year
+174.7%
3Y CAGR
+47.5%
5Y CAGR
+26.0%
10Y CAGR
+11.7%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
ROIV vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 15.2x median
Peer median unavailable
Revenue Growth
0.0%
vs +14.7% median
-100% below peer median
Net Margin
-3629.2%
vs -302.6% median
-1099% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
ROI ROIV Roivant Sciences Ltd. | $22.6B | — | 0.0% | -3629.2% | Buy | +18.3% |
BHV BHVN Biohaven Ltd. | $1.4B | — | — | — | Buy | +29.7% |
IMV IMVT Immunovant, Inc. | $7.3B | — | — | — | Buy | +27.3% |
KYM KYMR Kymera Therapeutics, Inc. | $7.4B | — | +23.7% | -612.2% | Buy | +24.5% |
PRA PRAX Praxis Precision Medicines, Inc. | $8.2B | — | +14.7% | — | Buy | +106.9% |
ABB ABBV AbbVie Inc. | $383.2B | 15.2x | +8.7% | 6.9% | Buy | +18.6% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
ROIV Dividend and Capital Return
ROIV returns 1.4% annually — null% through dividends and 1.4% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
1.4%
Dividend + buyback return per year
Buyback Yield
1.4%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
1Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$318M
Estimated Shares Retired
10M
Approx. Share Reduction
1.4%
Shares Outstanding
Current diluted share count from the screening snapshot
719M
At 1.4%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsROIV Investor Questions
Common questions answered from live analyst data and company financials.
01Is Roivant Sciences Ltd. (ROIV) stock a buy or sell in 2026?
Roivant Sciences Ltd. (ROIV) is rated Buy by Wall Street analysts as of 2026. Of 15 analysts covering the stock, 14 rate it Buy or Strong Buy, 1 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $37, implying +18.3% from the current price of $31.
02What is the ROIV stock price target for 2026?
The Wall Street consensus price target for ROIV is $37 based on 15 analyst estimates. The high-end target is $42 (+33.6% from today), and the low-end target is $30 (-4.5%).
03Is Roivant Sciences Ltd. (ROIV) stock overvalued in 2026?
Forward earnings data for ROIV is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
04What are the main risks for Roivant Sciences Ltd. (ROIV) stock in 2026?
The primary risks for ROIV in 2026 are: (1) Revenue Concentration — Full-year 2026 sales of US$8. (2) Pipeline Execution Risk — Despite a strong balance sheet, Roivant's ability to advance its diversified pipeline and acquire new assets successfully remains uncertain. (3) Net Income Volatility — The swing to quarterly net income of US$302. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Roivant Sciences Ltd.'s revenue and earnings forecast?
Analyst consensus estimates ROIV will report consensus revenue of $8M (0.0% year-over-year) and EPS of $-0.00 (+99.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $8M in revenue.
06When does Roivant Sciences Ltd. (ROIV) report its next earnings?
Roivant Sciences Ltd. is expected to report its next earnings on approximately 2026-07-01. Consensus expects EPS of $-0.29 and revenue of $4M. Over recent quarters, ROIV has beaten EPS estimates 83% of the time.
07How much free cash flow does Roivant Sciences Ltd. generate?
Roivant Sciences Ltd. (ROIV) had a free cash outflow of $759M in free cash flow over the trailing twelve months — a free cash flow margin of 9183.5%. ROIV returns capital to shareholders through and share repurchases ($318M TTM).